Patients receiving CFTR modulators have experienced improvement in clinical endpoints such as weight gain and augmented lung function, although outcomes with regard to CFRD pathogenesis have not been well-delineated [58]. Here, CFTR is linked to cystic fibrosis-related diabetes.